Name of Scheme

Artificial Intelligence (AI) and Microfluidic for Precision Medicine

External Deadline

Internal Deadline


[Licensing negotiation in progress]

[Invitation for Expression of Interest- Deadline: 28 March 2024]

We are inviting expressions of interest (EoI) for commercializing “Artificial Intelligence (AI) and Microfluidic for Precision Medicine” technology.  The innovation is developed by Professor Ngoc Duy DINH, of Department of Biomedical Engineering of The Chinese University of Hong Kong (CUHK Reference: 22/ENG/1151).

The Technology

Our invention is an innovative method to customize drug combination treatment for every individual in the world by implementing Artificial Intelligence, Big Data and Microfluidic Technology. Taking cancer as an example, due to the heterogeneity among cells, tumors and patients, these factors are contributing to the low efficiency of chemotherapy. Patients express distinct response towards the same therapy. Thus, our platform offers personalized drug treatment for patients with different genetic information, drug resistance and body status. Our invention aims to accelerate development of precision medicine.

Commercialization

The technology is now available for licensing on an exclusive basis.  In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development.  In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society.  Previous or existing business involvement and experience in this area is a plus.

This invitation of expression of interest is without prejudice.  We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.

Name of Scheme

Artificial Intelligence (AI) and Microfluidic for Precision Medicine

Description

[Licensing negotiation in progress]

[Invitation for Expression of Interest- Deadline: 28 March 2024]

We are inviting expressions of interest (EoI) for commercializing “Artificial Intelligence (AI) and Microfluidic for Precision Medicine” technology.  The innovation is developed by Professor Ngoc Duy DINH, of Department of Biomedical Engineering of The Chinese University of Hong Kong (CUHK Reference: 22/ENG/1151).

The Technology

Our invention is an innovative method to customize drug combination treatment for every individual in the world by implementing Artificial Intelligence, Big Data and Microfluidic Technology. Taking cancer as an example, due to the heterogeneity among cells, tumors and patients, these factors are contributing to the low efficiency of chemotherapy. Patients express distinct response towards the same therapy. Thus, our platform offers personalized drug treatment for patients with different genetic information, drug resistance and body status. Our invention aims to accelerate development of precision medicine.

Commercialization

The technology is now available for licensing on an exclusive basis.  In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development.  In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society.  Previous or existing business involvement and experience in this area is a plus.

This invitation of expression of interest is without prejudice.  We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.

Category

N/A

For inquiries about licensing opportunity, contact

Ms Fei Fei MIU

Office of Research and Knowledge Transfer Services

miufeifei@cuhk.edu.hk

Inventors

Professor Ngoc Duy DINH

Keywords

N/A